INBX - Company ID 0001739614
The table below shows Inhibrx, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue | $1.80M | $2.19M | $7.23M | $12.89M | $13.21M |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $191.64M | $110.19M | $71.44M | $73.50M | $47.91M |
| SG&A | $29.38M | $21.12M | $12.36M | $6.84M | $6.26M |
Inhibrx, Inc. reported annual revenue of $1.80M for fiscal year 2023. That is down 17.9% from $2.19M in fiscal 2022. Over the 5 fiscal years shown, annual revenue declined from $13.21M (FY 2019) to $1.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$219.22M |
| -$129.12M |
| -$76.56M |
| -$67.44M |
| -$43.71M |
| Income tax | $3.00K | $3.00K | $2.00K | $3.00K | $898.00K |
| Net income | -$241.36M | -$145.23M | -$81.77M | -$76.12M | -$51.40M |
| EPS (diluted) | -$5.12 | -$3.62 | -$2.15 | -$3.01 | - |